Competitor Analysis Influenza Vaccines

Date: May 22, 2011
Pages: 123
Price:
US$ 718.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CA322AFC11DEN
Leaflet:

Download PDF Leaflet

Competitor Analysis Influenza Vaccines
The present Competitive Intelligence Report about Influenza Vaccines provides a competitor evaluation in the field of marketed and novel prophylactic vaccines against seasonal and pandemic influenza viruses. Presentation of the vaccines is structured according to the manufacturing process: propagated in hens’ eggs or in cell culture, recombinant protein based vaccines and DNA based vaccines. Product description considers use of adjuvants and preservatives. Vaccines with nasal delivery are highlighted. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed vaccines and active projects in research and development for prophylaxis of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

1. Seasonal influenza vaccines
  1a) Cell-culture produced seasonal influenza vaccines
  1b) Egg-produced seasonal influenza vaccines
  1c) Recombinant Seasonal influenza vaccines
  1d) DNA-based seasonal influenza vaccines
  1e) Nasal delivery of seasonal influenza vaccines
  1f) Other seasonal influenza vaccines
2) Pandemic (swine) A(H1N1) influenza vaccines
  2a) Cell-culture produced pandemic (swine) A(H1N1) influenza vaccines
  2b) Egg-produced pandemic (swine) A(H1N1) influenza vaccines
  2c) Recombinant pandemic (swine) A(H1N1) influenza vaccines
  2d) DNA-based pandemic (swine) A(H1N1) influenza vaccines
  2e) Nasal delivery of pandemic (swine) A(H1N1) influenza vaccines
  2f) Other pandemic (swine) A(H1N1) influenza vaccines
3) Pandemic (avian) H5N1 influenza vaccines
  3a) Cell culture-produced pandemic (avian) H5N1 influenza vaccines
  3b) Egg-produced pandemic (avian) H5N1 influenza vaccines
  3c) Recombinant pandemic (avian) H5N1 influenza vaccines
  3d) DNA-based pandemic (avian) H5N1 influenza vaccines
  3e) Nasal delivery of pandemic (avian) H5N1 influenza vaccines
  3f) Other pandemic (avian) H5N1 influenza vaccines
4) Other & unspecified pandemic influenza vaccines
5) Universal influenza vaccines

Corporate Influenza Vaccine Product Portfolios and R&D Pipelines

A*STAR
Abbott
AlphaVax
Ajanta Pharma
Antigen Express
Astellas Pharma
AstraZeneca
Avimex Laboratories
Avir Green Hills Biotechnology
Baxter
Beijing Tiantan Biological Products
Bharat Biotech
Biological E
BiondVax Pharmaceuticals
Bionor Immuno
BioSante Pharmaceuticals
Changchun Institute of Biological Products
CSL Limited
CytoGenix
Cytos Biotechnology
Dynavax Technologies
Emergent BioSolutions
FluGen
Fraunhofer
G-Con
GenPhar
GlaxoSmithKline (GSK)
GlobeImmune
Green Cross
Hualan Biological Engineering Inc
Intercell
iBio, Inc.
Immune Targeting Systems
Immuno-Vaccine Technologies
Inovio
Inviragen
Jiangsu Yanshen Biological Technology
Johnson & Johnson (J&J)
Juvaris Bio-Therapeutics
Lanzhou Institute of Biological Products (LIBP)
Liquidia Technologies
Medicago
Mellow Hope (HTDS)
Merck & Co.
Mogam Research Institute
NanoBio
Nano-therapeutics
NasVax
National Institute of Allergy and Infectious Diseases (NIAID)
Novartis
Novavax
Okairos
Panacea Biotech
Pevion Biotech
Protein Sciences
Sanofi-Aventis
Sanofi Pasteur
SEEK
Shanghai Institute of Biological Products
Shenzhen Neptunus Interlong Bio-technique Company (Interlong)
Sinovac Biotech
SK Chemicals
Solvay Biologicals
TechnoVax
Temasek
UMN Pharma
University of Wisconsin
Variation Biotechnologies
Vaxart
Vaxin
VaxInnate
Vical
Zhejiang Tianyuan Bio-Pharmaceutical Co
Zydus Cadila

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top


Competitor Analysis: Malaria Vaccines & Therapeutics US$ 390.00 Aug, 2012 · 64 pages
Competitor Analysis: RSV Vaccines and Therapeutics US$ 315.00 Jun, 2012 · 30 pages
Competitor Analysis: HPV Vaccines US$ 170.00 May, 2010 · 18 pages
Competitor Analysis: CMV Vaccines & Therapeutics US$ 247.00 Aug, 2012 · 23 pages

Ask Your Question

Competitor Analysis Influenza Vaccines
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: